Clinical Study to Study Safety and Efficacy of herbal formulation - Aayudh Advance

A Randomized and Comparative Study to assess Safety and Efficacy of Supplemental Treatment of a herbal formulation - Aayudh Advance comprising essential oils in patients with Corona Virus 2019 (Covid-19)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/06/025977

Enrollment

120

Registered

2020-06-18

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Aayudh Advance: 15 ml four times a day before meal until the covid-19 negative or study duration completed Control Intervention1: Standard of care treatment: As per the Standard of care

Eligibility

Inclusion criteria

Inclusion criteria: Subject willing to sign informed consent. Subject age group of 18 years and above of both gender. All patients with COVID-19 PCR positive (within 7 days/high clinical suspicion admitted to Corona Virus study participating hospital will be eligible. Patients who are having mild to moderate symptoms of Covid-19 disease and tested positive for Covid-19 test.

Exclusion criteria

Exclusion criteria: Patients younger than 18 years. Women who are pregnant or who intend to become pregnant for the next three months after taking the drug. Patients allergic to type medications or any of the ingredient of the formulation. Patients with a neurological history (seizures, epilepsy, etc.). Patients with a previous history of psychiatric illnesses (depression, anxiety, suicide attempt). Patients with cardiac pathologies or relevant chronic diseases that in the judgment of the clinician recommend the non-inclusion of the patient in the study. Patients who would require artificial ventilation or oxygen supply. Very severe patients of Covid 19. Patients with severe hypertension, diabetes shall be excluded.

Design outcomes

Primary

Measure	Time frame
To compare the safety and efficacy of the Supplemental herbal formulation - Aayudh Advance with Standard treatment. Establish if the preventive administration of herbal formulation - Aayudh Advance attenuates the clinical manifestations of COVID-19 in people who become infected. Timepoint: every visit	—

Secondary

Measure	Time frame
Observing any side effects and serious adverse reaction of herbal formulation - Aayudh Advance Adjunctive medications required due to supplementary herbal formulation - Aayudh Advance treatmentTimepoint: Every Visit	—

Countries

India

Contacts

Public ContactDr Manish Rachchh

Ganatra Ayurveda & Panchkarma Clinic

vd.ganatra@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026